Literature DB >> 10217607

Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.

G Kersten1, T Hazendonk, C Beuvery.   

Abstract

Inactivated polio vaccine (IPV) was prepared with the Sabin strains, normally used for the attenuated live vaccine. The vaccine was characterized with respect to its antigenicity as determined by ELISA and biosensor analysis and its immunogenicity in rats. Compared with the vaccine prepared with virulent strains (Mahoney, MEF and Saukett) some distinct differences were found with regard to the interaction with glass vials (types 1 and 2) and antigenicity (type 3). The most profound difference however, was the immunogenicity of types 1 and 2. Standardized on the amount of virus, type 1 Sabin-IPV was about 3 times more immunogenic as compared to Mahoney-IPV. The immunogenicity of type 2 Sabin-IPV on the other hand was reduced approximately 10-fold, compared to MEF-IPV. Type 3 Sabin and Saukett IPV were comparable in immunogenicity but differences in antigenicity were evident. The lack of correlation between antigenicity and immunogenicity demonstrate that current IPV standards are not suitable to quantify IPV made from Sabin strains. The results indicate that future Sabin-IPV vaccines may have to contain virus amounts that are very different as compared to current IPV vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217607     DOI: 10.1016/s0264-410x(98)00409-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.

Authors:  Glynis Dunn; Dimitra Klapsa; Thomas Wilton; Lindsay Stone; Philip D Minor; Javier Martin
Journal:  PLoS Pathog       Date:  2015-08-27       Impact factor: 6.823

2.  An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.

Authors:  Viki Bockstal; Machteld M Tiemessen; Rogier Achterberg; Carlo Van Wordragen; Ad M Knaapen; Jan Serroyen; Wilfred E Marissen; Hanneke Schuitemaker; Roland Zahn
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

3.  A novel gamma radiation-inactivated sabin-based polio vaccine.

Authors:  Gregory J Tobin; John K Tobin; Elena K Gaidamakova; Taralyn J Wiggins; Ruth V Bushnell; Wai-Ming Lee; Vera Y Matrosova; Stephen J Dollery; Heather N Meeks; Diana Kouiavskaia; Konstantin Chumakov; Michael J Daly
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

4.  Development of an animal component free production process for Sabin inactivated polio vaccine.

Authors:  Diego A Suarez-Zuluaga; Leo A van der Pol; Aart G van 't Oever; Wilfried A M Bakker; Yvonne E Thomassen
Journal:  Vaccine X       Date:  2022-09-30

5.  Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Authors:  Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.